Tysabri

The most important adverse effect of natalizumab is progressive multifocal leukoencephalopathy (PML).1 Apart from PML, there are… (More)

Entyvio (vedolizumab), Takeda’s drug for inflammatory bowel disease (IBD), is in line to become the first integrin inhibitor to… (More)

INTRODUCTION Natalizumab is very effective at reducing relapses and delaying disease progression in patients with relapsing… (More)

Therapeutic monoclonal antibodies are potent new tools for a molecular targeted approach to modify the course of multiple… (More)

1061 that isn’t the problem, says ZymoGenetics chief executive Bruce Carter. Rather, it is because the acute hospitals that use… (More)

The US FDA recently approved the monoclonal antibody TYSABRI (natalizumab) for use in the treatment of adults with moderately to… (More)

The future of a promising treatment for multiple sclerosis (MS) is in question after two patients takinag the drug were diagnosed… (More)

Although the financial implications of Elan's and Biogen Idec's shock withdrawal from the market of the highly promising multiple… (More)

The future of several drugs for autoimmune disorders hangs in the balance after a third case of a rare neurological disorder was… (More)